Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash from Investing Activities (2021 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Cash from Investing Activities for 5 consecutive years, with -$40754.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 66.92% year-over-year to -$40754.0, compared with a TTM value of -$98080.0 through Dec 2025, up 8.75%, and an annual FY2025 reading of -$81742.0, up 31.99% over the prior year.
  • Cash from Investing Activities was -$40754.0 for Q4 2025 at Neuroone Medical Technologies, down from -$10607.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $1.8 million in Q1 2023 and bottomed at -$3.0 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$45228.6, with a median of -$33234.5 recorded in 2021.
  • The sharpest move saw Cash from Investing Activities tumbled 8546.56% in 2022, then soared 2054.91% in 2023.
  • Year by year, Cash from Investing Activities stood at -$61491.0 in 2021, then surged by 124.51% to $15069.0 in 2022, then tumbled by 346.41% to -$37131.0 in 2023, then skyrocketed by 34.24% to -$24416.0 in 2024, then crashed by 66.92% to -$40754.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for NMTC at -$40754.0 in Q4 2025, -$10607.0 in Q3 2025, and -$43548.0 in Q2 2025.